Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eluminex Starts Trials of Novel Trispecific Fusion mAb for Macular Edema

publication date: May 5, 2024

Suzhou’s Eluminex Biosciences was approved to start US trials of its novel trispecific fusion antibody aimed at treating diabetic macular edema. EB-105 targets VEGF-A, VEGF-B, placental growth factor, angiopoetin-2, and interleukin-6 receptor. Eluminex believes that high levels of IL-6 may cause persistent refractory edema in DME patients who are currently being treated with existing drugs. The ability of EB-105 to inhibit several biological pathways simultaneously may offer better efficacy than present therapies, it added. Eluminex has raised over $100 million from investors including Lilly Asia Ventures, Quan Capital, Hillhouse Ventures, and Cenova Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here